Skip to main content
SpringerLink
Log in

Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Retinoids constitute a very promising class of agents for the chemoprevention or treatment of breast cancer. These retinoids exert their biological activity through two distinct classes of retinoic acid (RA) receptors (R), the RAR isotypes (α, β, and γ) and the three RXR isotypes (α, β, and γ) and their numerous isoforms which bind as RXR/RAR heterodimers to the polymorphic cis-acting response elements of RA target genes. With respect to these numerous receptor sub-types, the retinoid-induced effects at the biological level include marked modifications with respect to both cell proliferation and cell death (apoptosis), and also in the induction of differentiation processes. The present study aims to characterize the effect which four retinoids (TTNPB, 9-cis-RA, LGD 1069, 4-HPR) with distinct RAR/RXR binding properties induced on various in vitro and in vivo mouse and human breast cancer models. The experiments with the retinoids were carried out in comparison with the anti-estrogen tamoxifen and the anti-progestagen RU-486 compounds. The results show that the 6 compounds under study were markedly more efficient in terms of growth inhibition in the human T-47D cell line when maintained under anchorage-independent culture conditions than when maintained under anchorage-dependent ones. While RU-486 exhibited a weak statistically significant (p < 0.05) influence on the growth of the T-47D stem cells, tamoxifen had a marked inhibitory influence on the growth of these cells. Of the four retinoids, 4-HPR was the least effective since the lowest doses tested (1 and 0.1 nM) exhibited no statistically (p > 0.05) significant influence on the growth of the stem cells. The most efficient retinoid was TTNPB. It was only at the highest dose (10 μM) that tamoxifen and RU-486 showed a weak inhibitory influence on the growth of the T-47D non-stem cells while all 4 retinoids exerted a significant inhibitory influence on the growth of these non-stem cells, with 4-HPR being the most efficient (P < 0.001) at the highest dose, but ineffective (P > 0.05) at the lowest. Tamoxifen and TTNPB were tested in vivo on hormone-senstive (HS) and hormone-insensitive (HI) strains of the MXT murine mammary carcin oma. While TTNPB appeared to be equally efficient in terms of growth inhibition in both MXT-HS and MXT-HI models, tamoxifen had only a marginal inhibitory influence on the growth of the MXT-HI strain but did inhibit growth in the case of the MXT-HS one. TTNPB was markedly more efficient than tamoxifen in terms of both inhibiting the cell proliferation level (measured by means of computer-assisted microscopy applied to Feulgen-stained nuclei, a method which enables the percentage of cells in the S phase of the cell cycle to be determined) and triggering cell death (measured by means of the determination of the transglutaminase activity) in both the MXT-HI and MXT-HS models. The very significant TTNPB-induced inhibition of the macroscopic MXT-HS growth rate relates to the triggering of cell death (apoptosis) rather than to an inhibition of cell proliferation. All these results clearly indicate that retinoids are very efficient agents against breast cancer, at least as efficient as tamoxifen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fisher B, Osborne CK, Margolese R, Bloomer W: Neoplasms of the breast. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer Medicine. Lea & Febiger, Philadelphia-London, Volume 1, 1993, pp T706–T774

    Google Scholar 

  2. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma. Suggestion for a new method of treatment with illustrative cases. Lancet 2: 104–107, 1896

    Google Scholar 

  3. Paridaens R, Leclercq G, Piccart M, Kiss R, Mattheiem W, Heuson JC: Comments on the treatment of breast cancer. In: Bulbrook RD (ed) Hormones of Cancer: 90 Years after Beatson. Cancer Surveys 5, 1986, pp 447–461

  4. Costa A, Sacchini V, Decensi A: Retinoids and tamoxifen in breast cancer chemoprevention. Int J Clin Lab Res 23: 53–55, 1993

    Google Scholar 

  5. Anzano MA, Byers SW, Smith JM, Peer CM, Mullen LT, Brown CC, Roberts AB, Sporn MB: Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 54: 4614–4617, 1994

    Google Scholar 

  6. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 56: 5566–5570, 1996

    Google Scholar 

  7. Cassano E, Coopmans de Yoldi G, Ferranti C, Costa A, Mascotti G, De Palo G, Veronesi U: Mammographic patterns in breast cancer chemoprevention with Fenretinide (4-HPR). Eur J Cancer 29A: 2161–2163, 1993

    Google Scholar 

  8. Gottardis MM, Lamph WW, Shalinsky DR, Wellstein A, Heyman RA: The efficacy of 9-cis-retinoic acid in experimental models of cancer. Breast Cancer Res Treat 38: 85–96, 1996

    Google Scholar 

  9. Dawson MI, Chao WR, Pine P, Jong L, Hobbs PD, Rudd CK, Quick TC, Niles RM, Zhang XK, Lombardo A, Ely KR, Shroot B, Fontana JA: Correlation of retinoic binding affinity to retinoic acid receptor α with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. Cancer Res 55: 4446–4451, 1995

    Google Scholar 

  10. Shao ZM, Dawson MI, Li XS, Rishi AK, Sheikh MS, Han QX, Ordonez JV, Shroot B, Fontana JA: p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 11: 493–504, 1995

    Google Scholar 

  11. James SY, Mackay AG, Colston KW: Vitamin D derivatives in combination with 9-cis-retinoic acid promote active cell death in breast cancer cells. J Mol Endocrinol 14: 391–394, 1995

    Google Scholar 

  12. Fanjul AN, Bouterfa H, Dawson M, Pfahl M: Potential role for retinoic acid receptor γ in the inhibition of breast cancer cells by selective retinoids and interferons. Cancer Res 56: 1571–1577, 1996

    Google Scholar 

  13. Liu Y, Lee MO, Wang HG, Li Y, Hashimoto Y, Klaus M, Reed JC, Zhang X: Retinoic acid receptor β mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol 16: 1138–1149, 1996

    Google Scholar 

  14. Lotan R: Retinoids in cancer chemoprevention. FASEB J 10: 1031–1039, 1996

    Google Scholar 

  15. Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 10: 940–954, 1996

    Google Scholar 

  16. Urbach J, Rando RR: Isomerization of all-trans-retinoic acid to 9-cis-retinoic acid. Biochem J 299: 459–465, 1994

    Google Scholar 

  17. Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E, Suto CM, Goldman ME, Heyman RA: Synthesis and structure-activity relationship of novel retinoid X receptor selective retinoids. J Med Chem 37: 2930–2941, 1994

    Google Scholar 

  18. Beard RL, Gil DW, Marler DK, Henry E, Colon DF, Gillett SJ, Arefieg T, Breen TS, Krauss H, Davies PJA, Chandraratna RAS: Structural basis for the differential RXR and RAR activity of stilbene retinoid analogs. Biorg Med Chem Lett 4: 1447–1452, 1994

    Google Scholar 

  19. Pellegrini R, Mariotti A, Tagliabue E, Bressau R, Bunone G, Coradini D, Della Valle G, Formelli F, Cleris L, Radice P, Pierotti MA, Colnghi MI, Ménard S: Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth Differ 6: 863–869, 1995

    Google Scholar 

  20. Kizaki M, Dawson MI, Heyman R, Elster E, Morosetti R, Pakkala S, Chen DL, Ueno H, Chao W, Morikawa M, Ikeda Y, Heber D, Pfahl M, Koeffler HP: Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro. Blood 87: 1977–1984, 1996

    Google Scholar 

  21. Beck CA, Zhang Y, Weigel NL, Edwards DP: Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J Biol Chem 271: 1209–1217, 1996

    Google Scholar 

  22. Watson CS, Medina D, Clark JH: Estrogen receptor characterization in a transplantable mouse mammary tumor. Cancer Res 37: 3344–3348, 1977

    Google Scholar 

  23. Danguy A, Kiss R, Leclercq G, Heuson JC, Pasteels JL: Morphology of MXT mouse mammary tumors. Correlation with growth characteristics and hormone sensitivity. Eur J Cancer Clin Oncol 22: 69–76, 1986

    Google Scholar 

  24. Kiss R, de Launoit Y, Danguy A, Paridaens R, Pasteels JL: Influence of pituitary grafts or prolactin administrations on the hormone sensitivity of ovarian hormone-independent mouse mammary MXT tumors. Cancer Res 49: 2945–2951, 1989

    Google Scholar 

  25. Briand P: Hormone-dependent mammary tumors in mice and rats as a model for human breast cancer (review). Anti-cancer Res 3: 273–282, 1983

    Google Scholar 

  26. Fingert HJ, Campisi J, Pardee AB: Cancer biology. Cell proliferation and differentiation. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer Medicine. Lea & Febiger, Philadelphia-London, Volume 1, 1993, pp 1–14

    Google Scholar 

  27. Piacentini M, Fesus L, Farrace MG, Ghibelli L, Piredda L, Melino G: The expression of ‘tissue’ transglutaminase in two human cancer cell lines is related with the programmed cell death (apoptosis). Eur J Cell Biol 54: 246–254, 1991

    Google Scholar 

  28. Horn V, Minucci S, Ogryzko VV, Adamson ED, Howard BH, Levein AA, Ozato K: RAR and RXR selective ligands cooperatively induce apoptosis and neuronal differentiation in P19 embryonal carcinoma cells. FASEB J 10: 1071–1077, 1996

    Google Scholar 

  29. Salmon I, Kiss R: Relationship between proliferative activity and ploidy level in a series of 530 human brain tumors including astrocytomas, meningiomas, schwannomas and metastases. Human Pathol 24: 329–335, 1993

    Google Scholar 

  30. Freake HC, Marcocci C, Iwasaki J, MacIntyre I: 1,25-dihydroxyvitamin D3 specifically binds to a human breast cancer cell line (T47D) and stimulates growth. Biochem Biophys Res Commun 101(4): 1131–1138, 1981

    Google Scholar 

  31. Camby I, Salmon I, Danguy A, Pasteels JL, Brotchi J, Martinez J, Kiss R: Influence of gastrin on human astrocytic tumor cell proliferation. J Natl Cancer Inst 88: 594–600, 1996

    Google Scholar 

  32. Janssen T, Darro F, Petein M, Raviv G, Pasteels JL, Kiss R, Schulman C: In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145 and PC3 models of the human prostate. Cancer 77: 144–149, 1996

    Google Scholar 

  33. Mosman T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assay. J Immunol Meth 65: 55–63, 1983

    Google Scholar 

  34. Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A, Boyd MR: Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res 51: 2515–2525, 1991

    Google Scholar 

  35. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR: Comparison of in vitro anticancer-drug-screening data generated with tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113–1118, 1990

    Google Scholar 

  36. Kiss R, Salmon I, Camby I, Gras S, Pasteels JL: Characterization of factors in routine laboratory protocols that significantly influence the Feulgen reaction. J Histochem Cytochem 41: 935–945, 1993

    Google Scholar 

  37. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275, 1951

    Google Scholar 

  38. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795–808, 1992

    Google Scholar 

  39. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, Rozzo C, Montaldo PG: Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 55: 853–861, 1995

    Google Scholar 

  40. Sporn MB, Newton DL: Chemoprevention of cancer with retinoids. Fed Proc 38: 2528–2534, 1979

    Google Scholar 

  41. Jing Y, Zhang J, Waxman S, Mira Y, Lopez R: Upregulation of cytokeratins 8 and 18 in human breast cancer T-47D cells is retinoid-specific and retinoic acid receptor-dependent. Differentiation 60: 109–117, 1996

    Google Scholar 

  42. Van Der Leede BM, Geertzema J, Vroom TM, Decimo D, Lutz Y, Van Der Saag PT, Van Der Burg B: Immunohistochemical analysis of retinoic acid receptor-alpha in human breast tumors: retinoic acid receptor-alpha expression correlates with proliferative activity. Am J Pathol 148: 1905–1914, 1996

    Google Scholar 

  43. Wang TT, Phang JM: Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Cancer Lett 107: 65–71, 1996

    Google Scholar 

  44. Fanjul AN, Delia D, Pierotti MA, Rideout D, Yu JQ, Pfahl M: 4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 271(37): 22441–22446, 1996

    Google Scholar 

  45. Kazmi SM, Plante RK, Visconti V, Lau CY: Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Cancer Res 56: 1056–1062, 1996

    Google Scholar 

  46. Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R: Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 89(16): 1191–1198, 1997

    Google Scholar 

  47. Standeven AM, Johnson AT, Escobar M, Chandraratna RA: Specific antagonist of retinoid toxicity in mice. Toxicol Appl Pharmacol 138: 169–175, 1996

    Google Scholar 

  48. Paridaens RJ, Danguy AJ, Leclercq G, Kiss R, Heuson JC: Effect of castration and 17 β-estradiol pulse on cell proliferation in the uterus and the MXT mouse mammary tumor. J Natl Cancer Inst 74: 1239–1246, 1985

    Google Scholar 

  49. Harris J, Morrow M, Norton L: Cancer of the breast (Chapter 36). Malignant tumors of the breast (Section 2). In: De Vita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. Fifth Edition. JB Lippincott Co., Philadelphia, 1997, pp 1557–1616

    Google Scholar 

  50. Pollack IF, Kawccki S: The efficacy of tamoxifen as an anti-proliferative agent in vitro for benign and malignant pediatric glial tumors. Pediatric Surg 22: 281–288, 1995

    Google Scholar 

  51. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MH, Law RE: Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345: 43–46, 1994

    Google Scholar 

  52. Berry J, Green BJ, Matheson DS: Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer. Eur J Cancer Clin Oncol 23: 517–520, 1987

    Google Scholar 

  53. Gottardis MM, Wagner RJ, Borden EC, Jordan VC: Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vitro and in vivo. Cancer Res 49: 4765–4769, 1989

    Google Scholar 

  54. Szende B, Schally AV, Comaru-Schally AM, Redding TW, Srkalovic G, Groot K, Lapis K, Timar J, Neill J, Mulchahey J: Cellular and molecular aspects of apoptosis in experimental tumors of animals treated with analogs of LHRH and somatostatin. In: Tomei LD, Cope FO (eds) Apoptosis: The Molecular Basis of Cell Death. Cold Spring Laboratory Press, 1991, pp 139–155

  55. Allegretto EA, McClurg MR, Lazarchik SB, Clemm DL, Kerner SA, Elgort MG, Boehm MF, White SK, Pike JW, Heyman RA: Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. J Biol Chem 258: 26625–26633, 1993

    Google Scholar 

  56. Pignatello MA, Kauffman FC, Levin AA: Multiple factors contribute to the toxicity of the aromatic retinoid, TTNPB (Ro 13-7410): binding affinities and disposition. Toxicol Appl Pharmacol 142: 319–327, 1997

    Google Scholar 

  57. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA: Chemoprevention of mammary carcinoma LGD1069 (targretin): an RXR-selective ligand. Cancer Res 56: 5566–5570, 1996

    Google Scholar 

  58. Sheikh MS, Zhao Z-M, Li X-S, Ordonez JV, Conley BA, Wu S, Dawson MJ, Han Q-X, Chao W-R, Quick T, Niles RM, Fontana JA: N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 16: 2477–2486, 1995

    Google Scholar 

  59. Viljoen TC, van Aswegen CH, du Plessis DJ: Binding of estradiol to whole prostatic DU-145 cells in the presence and absence of tamoxifen and acetylsalicylic acid. Prostate 27: 160–165, 1995

    Google Scholar 

  60. Terakawa N, Shimizu I, Tanizawa O, Matsumoto K: RU486, a progestin antagonist, binds to progesterone receptors in a human endometrial cancer cell line and reverses the growth inhibition by progestins. J Steroid Biochem 31: 161–166, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire d'Histologie, Faculté de Médicine, Université Libre de Bruxelles, Brussels, Belgium

    Francis Darro, Pierre Cahen, Alexandre Vianna, Christine Decaestecker, Carole Chaboteaux, Cinthia Ramos (Post-doctoral Fellow) & Robert Kiss (Research Associate with the Fonds National de la Recherche Scientifique)

  2. Centre Européen de Bioprospective, Rouen, France

    Francis Darro, Pierre Cahen, Bertrand Leblond, Alain Schoofs & Bernard Pourrias

  3. Department of Gynecology, Faculty of Medicine, Evangelical, University of Parana, Curitiba, Brasil

    Alexandre Vianna & Vinicius Budel

  4. Service de Chirurgie, Institut Jules Bordet, Brussels, Belgium

    Jean-Marie Nogaret

  5. Department of Ophthalmology, Faculty of Medicine, Evangelical University of Parana, Curitiba, Brasil

    Cinthia Ramos (Post-doctoral Fellow)

  6. Service d'Anatomie Pathologique, Institut Jules Bordet, Brussels, Belgium

    Michel Pétein

  7. FNRS, Belgium

    Robert Kiss (Research Associate with the Fonds National de la Recherche Scientifique)

Authors
  1. Francis Darro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierre Cahen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexandre Vianna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christine Decaestecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean-Marie Nogaret
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bertrand Leblond
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Carole Chaboteaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Cinthia Ramos
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michel Pétein
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Vinicius Budel
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Alain Schoofs
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Bernard Pourrias
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Robert Kiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Darro, F., Cahen, P., Vianna, A. et al. Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen. Breast Cancer Res Treat 51, 39–55 (1998). https://doi.org/10.1023/A:1006098124087

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006098124087

Search

Navigation